Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials-Reference-Cited by-同舟云学术

Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials

Published:2019-08 Issue:8 Volume:21 Page:1790-1800
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Giugliano Dario¹^ORCID,De Nicola Luca²,Maiorino Maria Ida³^ORCID,Bellastella Giuseppe¹,Esposito Katherine³

Affiliation:

1. Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical SciencesUniversity of Campania “L. Vanvitelli” Naples Italy

2. Division of Nephrology, Department of Advanced Medical and Surgical SciencesUniversity of Campania “L. Vanvitelli” Naples Italy

3. Diabetes Division, Department of Advanced Medical and Surgical SciencesUniversity of Campania “L. Vanvitelli” Naples Italy

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13743

Reference49 articles.

1. Changes in Diabetes-Related Complications in the United States, 1990–2010

2. Patient Characteristics and Outcomes by GN Subtype in ESRD

3. Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: pooled analysis of four cohort studies

4. New pharmacological strategies for protecting kidney function in type 2 diabetes

5. U.S. Food and Drug Administration. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.2008. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed February 25 2019.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide;Diabetes, Obesity and Metabolism;2024-09-02

2. Women's health and kidney protective medications;Current Opinion in Nephrology & Hypertension;2024-05-03

3. Sex-Related Aspects in Diabetic Kidney Disease—An Update;Journal of Clinical Medicine;2023-04-12

4. Higher Plasma Levels of Valerate Produced by Gut Microbiota May Have a Beneficial Impact on Renal Function;Journal of the American Nutrition Association;2023-02-14

5. The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes;Cureus;2023-01-07